This was the stock's second consecutive day of gains.
By Sneha S K and Sriparna Roy (Reuters) - The U.S. Food and Drug Administration said on Friday that it has approved an ...
By Sneha S K and Sriparna Roy (Reuters) -The U.S. Food and Drug Administration said on Friday that it has approved an ...
Princeton molecular biologist Bonnie Bassler, emeritus professors Larry Martin Bartels and Ingrid Daubechies, and ...
Highlights,Bristol-Myers Squibb manages its debt effectively with solid earnings.,A substantial cash reserve supports the ...
CytomX’s workforce cuts could leave the biotech with fewer than 75 employees as it focuses resources on its wholly owned ...
GORTEC, known as Head and Neck Radiation Oncology Group, today announced that the randomized Phase 3 NIVOPOSTOP GORTEC 2018-01 trial evaluating nivolumab, Bristol Myers Squibb's anti-PD-1 therapy, as ...
Emerging evidence supports the argument that psoriatic arthritis arises from two pathways and that affected immune cells may ...
The FDA has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), a new subcutaneous injection formulation of Opdivo.
Cancer-focused CytomX Therapeutics Inc. will lay off 40% of its workforce — about 50 employees — to help extend its cash into ...
Bristol Myers Squibb Co. closed $4.40 below its 52-week high ($61.08), which the company achieved on November 11th.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback